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Abstract 
The interactions of HSA with DA have received great attention nowadays due 
to its significant effect in the biomedical field and overall health. The main 
aim of this work is to examine the interaction between DA and HSA at physi-
ological conditions. Upon addition of DA to HSA, the fluorescence emission 
was quenched with quenching constant Kq = 1.32 × 109 L∙mol−1∙s−1 and the 
binding constant of DA with HSA is found to be K = 4.4 × 102 mainly indi-
cating dynamic quenching. The HSA conformation was altered upon binding 
of DA to HSA with an increase in α-helix and a decrease in β-sheets suggest-
ing unfolding of HSA secondary structure due to weak intermolecular inte-
raction with HSA. In view of the evidence presented, it is important to un-
derstand the details of the interactions of HSA with DA which will be crucial 
in the design of new DA-inspired drugs and help revealing vital details to 
better understand the HSA’s role as a transporter for many drugs. 
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1. Introduction 
Dopamine (DA), chemical structure provided in the top part of Figure 1 [1], is a 
catecholamine neurotransmitter synthesized within the brain in the dopaminer-
gic neurons and is involved in regulating multiple functions including move-
ment and memory. DA transmits signals between neurons throughout human  
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Figure 1. Chemical structure of dopamine hydrochloride (top). 
Secondary structure of HSA (bottom). 
 
brain and body. The elevated or reduced dopamine level may cause memory loss 
related diseases, attention deficit, hyperactivity disorder, daydreaming and not 
being able to stay on task. Any changes in the levels of this vital neurotransmit-
ter chemical have been proven to be related to several dopaminergic neurologi-
cal diseases depending on the affected region in the brain [2] [3] [4] [5]. For 
example, neurocognitive disorders related to memory, attention, and prob-
lem-solving functions result from decline of DA in frontal lobes of the brain 
which controls the flow of information from other areas of the brain [6] [7] [8]. 
Therefore, DA is considered a major target for drug designing applied in the 
treatment of neurological diseases. 
Inadequate DA levels due to the loss of DA-producing cells have been related 
Parkinson’s disease which is associated with a loss in the ability of well con-
trolled movements [9] [10] [11]. Despite the ongoing research to understand 
these devastating disorders, the sophisticated causes of dopaminergic cells’ loss 
in Parkinson’s disease are only partially understood. 
1.1. Human Serum Albumin (HSA) 
Human serum albumin (HSA), secondary structure provided in the bottom part 
I. M. Khalid et al. 
 
 
DOI: 10.4236/ojbiphy.2019.92009 112 Open Journal of Biophysics 
 
of Figure 1 [12], is the most prominent protein in the human blood plasma and 
it constitutes about 60% of the total plasma proteins. It is a single-chain poly-
peptide consisting of 585 amino acids residues stabilized by 17 disulfide bridges 
and has a molecular mass of 66.5 kDa. HSA high importance is due to its many 
important physiological functions [13] [14]. HSA is made up of three similar 
structural domains I, II, and III. Each domain is further divided into subdomain 
A and B. It is well documented that subdomains IIA and IIIA are known as the 
major drug binding sites for the majority of heterocyclic and aromatic com-
pounds [12] [13]. Recent investigation has demonstrated the capacity of subdo-
main IB in binding drugs making it a potential for various drugs delivery [15]. 
These binding sites empower the HSA with an exceptional ability in binding 
various ligands, which adds to its biological importance in delivering number of 
drugs in the blood system to their targeting organs/tissues within the human 
body [16] [17]. Generally, HSA binds reversibly with wide range of drugs how-
ever some drugs with high affinity for HSA limit the drug distribution—of free 
form and the bound form—as well as the elimination of the drugs. In addition, 
the HAS-drug interactions play an important role in understanding the efficien-
cy of the drug as determined by the free fraction of the drug [18] [19]. 
1.2. Alzheimer’s Disease (AD) 
AD, affecting millions of individuals worldwide, is an irreversible neurodege-
nerative disorder characterized by progressive cognitive decline and dementia 
[20]. The decline in cognitive function affects recent memory first then slowly 
spreads to other regions of the brain. As of now, the exact cause of AD is not 
known and currently there is no cure for this devastating disease. Therefore, any 
available treatment is meant to slow the progression of AD and relieves its 
symptoms. It has been suggested and well documented that AD originates in the 
brain [21] but a recent investigation have indicated that AD could have been 
triggered by breakdowns elsewhere in the body. This finding makes is promising 
in preventing AD from reaching the brain if proper drug targets the toxin pro-
tein and removes it while in the blood without the need to act directly on the 
brain, which is a very challenging task to accomplish and hard-to-reach target 
safely [22] [23]. In addition, electrical signaling responsible for learning and 
memory is usually diminished in people with AD [24]. 
1.3. Parkinson’s Disease (PD) 
PD, a neurological disorder that affects movement control, neurons progressively 
degenerate and as a result, the amount of DA available for neurotransmission in 
the brain is lowered [25] [26]. The main symptoms of PD due to DA imbalance 
include resting tremor, rigidity, a gradual slowness of natural movement, poor 
balance and diminished motor coordination [9] [27]. 
The underlying cause of PD is the progressive loss of dopaminergic neurons 
in some neurons and the presence of Lewy bodies—abnormal protein aggre-
gates—in the remaining neurons [24]. The neural loss leads to dopamine defi-
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ciency which is believed to be responsible neurodegenerative “motor disease”. 
The main therapy to treat PD is by dopamine replacement merely relieves the 
associated symptoms but the disease continues its progression. Therefore, there 
is a need for understanding the process of the neurological degeneration to de-
velop effective drugs to stop the degeneration [10] [11]. 
In addition to PD, alterations in the dopamine levels have been consistently 
observed and reported in AD patients, including lower levels of dopamine (DA) 
[28] [29]. Although research investigations have resulted in developing few 
theories about AD, until now there is no definite reason standing out as the 
cause of this disturbing disease [21] [30] [31]. There is evidence supporting the 
conception that dopaminergic system dysfunction has a role in cognitive decline 
symptoms of AD, however, the cause of dopaminergic system dysfunction in AD 
remains to be elucidated [2] [24] [32]. 
Drug binding to HSA plays a major role in the drug efficacy—the ability of a 
drug to provide a beneficial effect—which is affected by drug distribution—the 
process of delivering a drug from the plasma to the tissue(s) where the drug’s ac-
tions are needed. Most of the drugs used by humans are bound to HSA which 
influences the drug distribution, absorption and efficiency [15] [16] [17] [18] 
[19] [33] [34] [35]. Since dopamine is recognized for its high pharmaceutical 
value as a potential candidate for treatment of neurological disorders such as AD 
and PD [8] [36] and it’s binding to HSA is not quite understood, therefore, the 
interaction of dopamine, a potential drug, with HSA is highly important to bet-
ter understand the drug-protein complex in terms of structural changes and sta-
bility to better elucidate its pharmacological importance. Therefore, the interac-
tion of dopamine and HSA is crucial to better understand the HSA-DA com-
plexation, provide significant information about HSA-DA stability as a complex, 
and underline the role of HSA in delivering DA to the blood stream. Similar to 
previous investigations with various other drugs [37] [38], this endeavor is fu-
eled by spectroscopic characterization to investigate the interaction between the 
HSA and DA and determine the complex stability associated with this binding. 
To reach this, we used fluorescence in combination with UV absorption spec-
troscopy and Fourier transform infrared (FTIR) spectroscopy to study the inte-
raction of DA with HSA to characterize the effect of this drug on HSA confor-
mational changes resulting from such complex. FTIR spectroscopy is reliable in 
monitoring conformational changes when proteins interact with drugs due to 
detection of functional groups’ changes due to interactions between the drug 
and the HSA thus affecting the overall secondary structure of the protein. Simi-
lar to other chemical compound, proteins have amide groups with the general 
structure of (—C(=O)–N—) which are clearly detected by FTIR. Therefore, any 
changes resulting from stabilization effects due to intermolecular forces, will 
cause changes to vibrational modes of the amide groups of the proteins. Similar-
ly, fluorescence spectroscopy is a powerful analytical chemistry technique in 
providing structural changes information due to quenching upon intermolecular 
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forces. Thus, fluorescence contributes in providing data to calculate binding 
constants and binding sites. 
2. Experimental 
2.1. Samples’ Preparations and Materials 
HSA protein (66,500 Da) and dopamine (189.2 g/mol) in powder form were 
purchased from Sigma Aldrich chemical company and were used without any 
further purifications. HSA stock solution was prepared in a concentration of 80 
mg/ml dissolved in phosphate buffered saline with pH of 7.4 which corresponds 
to 1.2 mM. The final concentration of HSA in the HSA-DA complex was 40 
mg/ml equivalent to molarity of 0.6 mM which is comparable to its concentra-
tion in the blood [15]. 
Dopamine stock solution with molarity of 4.8 mM, was prepared by dissolving 
dopamine hydrochloride in enough distilled water to prepare DA stock solution. 
DA standard solutions were prepared by successive dilutions. The HSA-DA 
complexes were prepared by mixing equal volumes of 1.2 mM HSA molarity and 
each of the standard DA solutions. The final concentration of HSA was kept at 
(40 mg/ml) in all samples while the concentrations of dopamine in the final HSA 
dopamine solutions was reduced to be as (0.15 mM, 0.3 mM, 0.4 mM, 0.5 mM, 
0.6 mM, 1.0 mM, 1.2 mM and 2.4 mM). 
2.2. Thin Film Preparation 
Silicon windows (NICODOM Ltd.) were used as spectroscopic cell window. 60 
µl of each sample of HSA-DA was spread on silicon window using spincoater to 
obtain equal thickness of each sample, then incubator was used to evaporate the 
solvent to obtain transparent thin film on the silicon window. All solutions were 
prepared at the same time at room temperature and were stored under the same 
conditions. 
3. Instrumentation 
3.1. FT-IR Spectroscopic Measurements 
The FT-IR measurements were obtained used Bruker IFS 66/S spectrophotome-
ter equipped with a liquid nitrogen-cooled MCT detector and KBr beam splitter. 
Silicon windows (NICODOM Ltd) were used as spectroscopic cell windows. 
Complexes’ solutions (0.15, 0.3, 0.6, 0.7, 0.9) mM were prepared at room tem-
perature. 60 µL of each sample of HSA-DA was spread on silicon window using 
spin coater to obtain equal thickness of each sample, and then was incubated for 
two hours to evaporate the solvent in order to obtain transparent thin film on 
the silicon window. The spectrophotometer was continuously purged with dry 
air during the measurements. The absorption spectra were obtained in the range 
of (400 - 4000) cm−1. A spectrum was taken as an average of 60 scans to enhance 
the signal to noise ratio, and the spectral resolution was at 4 cm−1. The aperture 
used in this study was 8 mm, since it gave the best signal to noise ratio. Baseline 
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correction, normalization and peak areas calculations were performed for all the 
spectra by OPUS software. The peak positions were determined using the second 
derivative of the spectra. The infrared spectra of HSA and the HSA-DA com-
plexes were obtained in the region of (1200 - 1700) cm−1. The FTIR spectrum of 
free HSA was acquired by subtracting the absorption spectrum of the buffer so-
lution from the spectrum of the protein solution. For the net interaction effect, 
the difference spectra {(HSA-DA) - (HSA)} were generated using the featureless 
region of the spectra at (1800 - 2200) cm−1. 
3.2. UV-VIS Absorption Spectra 
The data was collected using 5 µL samples using NanoDrop ND-1000 Spectro-
photometer for the free HSA (40 mg/ml or 0.6 mM) and for the HSA-DA com-
plexes solutions with the following concentrations (0.15, 0.3, 0.4, 0.5, 0.6, 1.0, 
1.2, and 2.4) mM. UV measurements were repeated for all the samples and no 
signiﬁcant differences were observed. The UV-absorption spectra of HSA-DA 
complex are obtained at the wavelength of 280 nm. 
3.3. Fluorescence 
The fluorescence measurements were obtained using NanoDrop ND-3300 Flu-
orospectometer for the following complexes concentration (0.15, 0.3, 0.4, 0.5, 
0.6, 1.0, 1.2, and 2.4) mM at 25˚C. The excitation source comes from one of 
three solid-state light emitting diodes (LEDs) including UV LED with maximum 
excitation 365 nm, Blue LED with excitation 470 nm, and white LED from 500 to 
650 nm excitation. A 2048-element CCD array detector covering 400 - 750 nm, 
is connected by an optical fibre to the optical measurement surface. The excita-
tion is done at the wavelength of 360 nm and the maximum emission wave-
length is at 440 nm. 
4. Results 
4.1. UV-Absorption Spectroscopy 
The UV absorbance spectra of different concentration of dopamine with a fixed 
concentration of HSA which were scanned over a range of 220 - 350 nm are 
presented in Figure 2. Each spectrum indicates two absorption maximum wave-
lengths at about 230 and 280 nm. The figure shows direct relationship between 
the increase in peak intensity of the HSA-DA complex and the concentration of 
the DA. This increase in intensity is due to interaction between HSA and DA as 
monitored in buffered solution by scanning the wavelengths. As indicated in the 
figure, there is a clear absorption signal for free DA. 
The reciprocal plot of 1/(A − Ao) versus (1/l) is linear as indicated in Figure 3. 
When a fixed concentration of HSA was allowed to complex with various 
amounts of DA, there is a linear increase in the UV absorbance of HSA. A bind-
ing constant for the HSA-DA complex was calculated using UV spectra accord-
ing to published methods [16] with the assumption that there is one-to-one  
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Figure 2. UV absorbance spectra of HSA-DA in 0.1 M PBS with pH 7.4 at 25˚C. 
Free HSA (40 mg/mL, 0.6 mM) and free HSA with different DA concentrations 
(a = free DA (4.8 mM), b = free HSA (0.6 mM), c-i correspond to HSA-DA 
complexes with (0. 3, 0.4, 0.5, 0.6, 1.0, 1.2 and 2.4) mM DA respectively. 
 
 
Figure 3. The plot of 1/(A−A0) vs. 1/l for free HSA (40 mg/mL, 0.6 mM) and 
with different HSA-DA complex concentrations in 0.1 M PBS with pH 7.4. 
 
interaction between HSA and DA in aqueous solution to establish chemical 
equilibrium as in the following equation. 
 :HSA DA HSA DA+ ↔                          (1) 
The corresponding formation/binding constant: 
[ ] [ ][ ]:  K HSA DA DA HSA=                   (2) 
on the following equation. 
( ) ( ) ( )0 0 01 1 1 1A A A A k A A l∞− = − + − ∗              (3) 
where Ao corresponds to the initial absorption of HSA at 280 nm in the absence 
of DA, A∞ is the final absorption of the HSA, and A is the recorded absorption at 
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different DA concentration (l). 
The binding constant (K) for HSA-DA complex was estimated from the ratio 
of the intercept to the slope and was found to be 8.54 × 102 M−1. The value for 
the binding constant is an indication of a weak intermolecular force interaction 
between the HSA and DA when compared to reported HSA-drug interaction 
with binding constant in the range of 104 and 106 M−1 [39] The importance of the 
binding constant value stems from its valuable application in drug delivery and 
pharmacokinetics [17] therefore, absorbance measurements were constantly re-
peated and similar results were obtained consistently. In addition, absorbance 
spectra were recorded for DA free with various concentrations corresponding to 
those of DA concentrations in the final HSA-DA complex. To further investigate 
the nature of the complexation-interaction, the absorbance value from the spec-
tra of free HSA was added to the absorbance value of the free HSA at 280 nm. 
The corresponding added absorbances’ values clearly indicate that the signal ob-
tained for the various individual added concentrations of the free HSA and free 
DA are comparable in magnitude to those of HSA-DA complex with same final 
concentration. This result supports the speculation that the interaction between 
HSA and DA is weak interaction. 
4.2. Fluorescence Emission Spectroscopy 
The emission spectra in the range of 400 to 750 nm were obtained for HSA-DA 
spectra are shown in Figure 4. When a fixed concentration of HSA is titrated 
with various amounts of DA, a decrease in the fluorescence emission of HSA is 
clearly presented. The quenching took place in a concentration dependent man-
ner; an increase in DA concentration led to decrease in HSA fluorescence inten-
sity. It is well established that HSA fluorescence is mainly due to Tryptophan 
(Trp), which is located at 214 position of subdomain IIA with very minor con-
tribution from tyrosine (Try) and phenylalanine which provide very low quan-
tum yields and therefore can be ignored [19] As a result, the fluorescence 
quenching is caused by addition of different concentrations of DA which causes 
quenching of fluorescence emission. This quenching could be a result of DA 
binding to HSA – a major drug carrier protein in the human blood plasma. 
Another reason is the possibility of formation of HSA-DA complex. There is no 
noticeable peak positional shift indicating that no major structural alternations 
of HSA upon binding with DA. Peak shifts, appearance of new peaks, disap-
pearance of existing peaks or various combinations of the mentioned are main 
characteristic of major structural changes. 
The HSA fluorescence is decreased upon increasing concentrations of DA, 
which indicates that the DA is interacting with HSA in the surrounding of the 
HSA main fluorescent residue Trp214 in subdomain IIA. The interaction be-
tween the DA and HSA can affect HSA fluorescence upon binding to DA due to 
the quenching ability of a tryptophan residue upon colliding with DA. Careful 
examination of the absorption spectra does not show and major changes and  
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Figure 4. Fluorescence emission spectra of free HSA and HSA-DA in 0.1 M PBS 
with pH 7.4, λex = 360 nm, λem = 439 and temperature at 25˚C. a = Free HSA (40 
mg/mL, 0.6 mM), i = free DA (4.8 mM), and (b-h) correspond to HSA with dif-
ferent DA concentrations (b = 0. 3, 0.4, 0.5, 0.6, 1.0, 1.2, and 2.4) mM DA. 
 
very little changes is observed on the absorption spectra of the HSA shape as the 
DA concentration is added which is an indication of minor conformational 
changes due to collisional quenching [40]. 
Further, to elucidate the nature of the quenching mechanism as static or dy-
namic in the HSA-DA system, Stern-Volmer equation [35] is used to plot Fo/F 
versus l and the result is shown in Figure 5. The Stern-Volmer plot is non-linear, 
indicating that both types of static and dynamic quenching occur. HSA is 
quenched both by collisions and by complex formation with DA. Hence, 
[ ]( ) [ ]( )0 1 1sv DF F K DA K DA= + ∗ +                (4) 
where F and F0 are the fluorescence intensities with and without quencher, KD is 
the dynamic quenching constant of the biomolecule and Ksv is the Stern-Volmer 
quenching constant due to static quenching. This modified second order form of 
the Stern-Volmer equation with respect to DA concentration, accounts for the 
both static and dynamic quenching occur for the same fluorophore. When 
quenching is due to static quenching, the second parenthesis in Equation (4) is 
ignored and when the quenching is dynamic the first parenthesis is ignored. 
However, when both static and dynamic quenching are present, one must ac-
count for each type. 
Fluorescence quenching can be induced by different mechanisms, which are 
usually classified into dynamic and static quenching. Dynamic quenching arises 
from collisional encounters between the fluorophore and quencher, and static 
quenching resulting from the formation of a ground state complex between the 
fluorophore and the quencher [40]. 
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Figure 5. The Stern-Volmer plot for HSA-DA complexes. 
 
To further understand the nature of quenching, the quadratic equation was 
solved using Excel for the KD and KSV values which were found to be KD = KSV = 
6.60 M−1. 
Using calculated KD value of 6.6 M−1 and τ0 as 5 × 10−9 s for HSA [40] which is 
typical for diffusion controlled reaction, the quenching constant, kq, is calculated 
from the 0sv qk k τ=  relation according to Stern-Volmer equation and which is 
determined to 1.32 × 109 L∙mol−1∙s−1 which is about the same as for collisional 
dynamic quenching constant for various quenchers with biopolymer (maximum 
value of 2 × 1010 L∙mol−1∙s−1) [12] [13]. This result implies that quenching is 
mainly due to dynamic collision and not to complex formation, but rather a dy-
namic quenching is mainly dominated [40] [41]. 
4.3. Accessibility of Tryptophan in HSA to Quenching by DA Using 
Fluorescence 
When dynamic collisional quenching dominates as quenching type of fluores-
cence for HSA with drugs, it usually results in deviation from linearity of 
Stern-Volmer plots. Therefore, it becomes necessary to further analyze the 
non-linear Stern-Volmer plots to determine if the quenching is purely collisional 
and to determine the accessibility fluorophores. Hence the following modified 
Stern-Volmer can be used: [40]. 
( ) [ ]( ) ( )0 1 1 1a a aF F f K DA f= ∗ +               (5) 
where F∆  is the difference between the unquenched fluorescence and the 
quenched fluorescence, fa is the fraction of the initial fluorescence that is accessi-
ble to quencher, Ka is the Stern-Volmer quenching constant of the accessible 
fraction, and [DA] is the dopamine concentration. The Ka can be calculated 
from the slope of the straight-line equation resulting from plotting Fo/( F∆ ) vs. 
1/[DA] as shown in Figure 6. The obtained value of effective binding constant,  
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Figure 6. Modified Stern-Volmer plot for HSA-DA complexes for accessibility determi-
nation. 
 
Ka is determined to be determined to be 4.4 × 102 M−1 and the accessible fraction 
fa = 0.05 indicating that the Trp214 is not accessible for biding with DA which is 
in agreement with the small effective binding constant. 
4.4. FT-IR Spectroscopy 
FT-IR is used widely to analyze IR bands of structural characterization of pro-
teins and provide clear information of any changes might occur due to various 
changes leading to decrease/increase in intensities of the original peaks as well as 
any shifts (blue/red due to interaction and or structural changes). HSA shows 
number of amide bands due to vibrations of various peptides within the protein. 
[42] Specifically, the amide groups of the peptides represent characteristic vibra-
tional modes (amide modes) which are sensitive to protein structures and any 
incurred changes might cause structural changes. IR spectral data for the HSA 
give rise to nine characteristic IR absorption bands, namely, amide A, B, and 
I-VII [43] [44] [45]. 
Amide I band ranges from 1700 to 1600 cm−1 and is mainly due to C=O stret-
ching vibrations of the peptide linkages. Amide II in the range of 1600 - 1480 
cm−1 is due to the coupling of the N—H in-plane bending to C—N stretching 
vibration, while amide III band ranging from 1330 to 1220 cm−1 is due to the 
C—N stretching mode coupled to the in-plane N—H bending mode [45]. 
The FT-IR absorption spectra in the region of (1800 - 1200) cm−1 are shown in 
Figure 7 for HSA and various HSA-DA complexes while HSA second deriva-
tives are shown in Figure 7 for free HSA (bottom) and HSA-DA complexes 
(top) while the difference spectra corresponding to free HSA and HSA-DA 
complex with various DA concentrations are shown in Figure 8. In addition, 
band assignments for the same spectra are presented in Table 1 according to re-
gion and DA concentrations. The second derivative of free HSA is shown in  
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Figure 7. The FT-IR spectrum of 0.6 mM HSA free (bottom) and the spectra (second de-
rivative) of DA-HSA complex (top) (a-f). DA concentration of 0.0 mM, 0.3 mM, 0.4 mM, 
0.5 mM, 0.6 mM and 0.7 mM. 
 
 
Figure 8. FT-IR spectra (top two curves, a (HSA free) and b (HSA + 0.7 mM DA) and 
differences spectra of HSA free and various DA-HSA complexes (c, d, e, f and g) with 
concentration of (0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM and 0.7 mM). 
 
Figure 8 (bottom) where the spectra is dominated by absorbance bands of amide 
I and amide II at 1655 cm−1 1540 cm−1 respectively. It is clear from the figure that 
as the DA concentration increases, the intensity of the 1655 cm−1 1540 cm−1 
peaks decrease. 
For DA-HSA interaction, the amide bands of HSA infrared spectra over all  
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Table 1. absorption peak assignment (in wavenumbers, cm−1) for HSA-DA at different 
concentration. 
Bands Range (cm−1) Free HSA DA concentrations 
Amide I 1700 - 1600 0.0 0.3 mM 0.4 mM 0.5 mM 0.6 mM 0.7 mM 
 β-sheets 1609 --- 1609 --- 1610 1610 
 β-sheets 1622 1621 1622 1622 1623 1623 
 Random 1636 1636 1636 1636 1636 1636 
 α-helix 1656 1654 1655 1655 1655 1655 
 Turns 1681 1681 1681 1680 1680 1681 
 β-sheets 1695 1695 1695 1695 1695 1695 
Amide II 1600 - 1480       
 β-sheets 1493 1494 1494 1495 1495 1494 
 Random 1520 1523 1521 1523 --- --- 
 α-helix 1540 1542 1543 1543 1544 1544 
 Turn 1574 1575 1576 1576 1575 1575 
 β-sheets 1592 1594 1593 1593 1593 1593 
Amide III 1320 - 1220       
 β-sheets 1231 1231 1231 1231 1231 1231 
 β-sheets 1245 1245 1245 1245 1245 1245 
 Random 1268 1271 1268 1267 1270 1268 
 turn 1294 1293 1293 1293 1291 1290 
 α-helix 1310 1309 1310 1310 1310 1310 
 
shift is listed clearly in Table 1. In amide I band, the peak positions have shifted 
from the HSA free to HSA-DA after addition of 0.7 mM DA as follows: 1622  
1623 cm−1, 1656  1654 cm−1, 1681  1680 cm−1. In addition, the peak at 1609 
cm−1 was fluctuating disappearing and appearing at various concentrations as 
shown in the table. For amide II, the peak positions have shifted as follow: 1493 
 1494 cm−1, 1520  1523 cm−1 and disappeared at the last two highest DA 
concentration, 1540 1544 cm−1, 1574  1575 cm-1 and 1592  1593 cm−1. In 
amide III region, the only peak shift is on: 1294  1290 cm−1. 
The 1656 cm−1 and 1540 cm−1, which correspond to amide I and amide II, re-
spectively represent the location of both the amide bonds orientation are sensi-
tive to the HSA secondary structure because both groups of C=O and the N-H 
bonds are involved in the hydrogen bonding that takes place between the differ-
ent elements of secondary structure [17] [46]. The overall change in peaks posi-
tions indicate HSA secondary structural changes due to interaction with DA. 
This shift in peak positions is mainly contributed to collisional electrostatic in-
teraction between the HSA and the DA. Shifts to lower wavenumbers for the 
major peak in amide I i.e. 1656  1654 cm−1 is mainly due to stabilization by in-
termolecular interaction between the non-bonding pair of electrons on the oxy-
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gen of the carbonyl C=O and the hydrogen of N—H thus causing the corres-
ponding amide II shift from 1540 to 1544 cm−1. Looking at the overall data in 
Table 1, it is obvious that the peak change (appearance, disappearance or shift) 
was stabilized or reached a steady behavior when the ratio of DA to HSA was 
approaching 1, specifically when the DA concentration reached 0.6 mM which 
corresponds to 1:1 ratio with the HSA and beyond. 
FT-IR spectra for the HSA-DA interaction are shown in Figure 8. The FT-IR 
spectra (top two curves) and difference spectra {HSA-DA complex—HSA free} 
for HSA-DA different ratios complexes in amide I and amide II regions are 
clearly presented. There is no appearance of any new peaks or major shift in 
peak position. However, in amide I region, there is a negative peak at 1655 cm−1 
with little shift of position that increases in intensity as the DA concentration is 
increased which corresponds to increase in HSA-DA complex concentration. 
Similar behavior is noted in amide II region with a negative feature at 1542 cm−1. 
The negative peaks behavior is attributed to the change in intensity of amide I 
and II bands which is a result of change of the secondary structure of HSA after 
combination with DA due to intermolecular interaction between the DA and the 
C=O and or N—H groups [46] [47]. 
The component bands of three amide regions, I, II and III were attributed ac-
cording to the well-established principle [48] [49] as follows: the bands in the 
range of 1610 - 1640 cm−1 are generally assigned to -sheet, bands in the range 
1640 - 1650 cm−1 correspond to random coil, bands in the range 1650 - 1658 
cm−1 are attributed to α-helix and the 1660 - 1700 cm−1 bands correspond to 
β-turn structure. The absorption bands in amide II consist of four components 
assigned in the following order: 1488 - 1500 cm−1 to β-sheets, 1504 - 1525 cm−1 to 
random coil, 1527 - 1560 cm−1 to α-helix and 1564 - 1585 cm−1 to turn structure. 
The component bands of amide III have been assigned as follows: 1330 - 1290 
cm−1 to α-helix, 1290 - 1270 cm−1 to β-turn and 1220 - 1250 cm−1 to β-sheets. 
Percentage determination of the contribution of each secondary structural ele-
ment in the HSA-DA complex secondary structure was carried out based on the 
assignment criterion for each of the HSA free and after the interaction with DA 
in amides I, II, and III. The quantitative analysis of the HSA was performed to 
determine any change in the secondary structure of HSA due to complexation 
with DA. 
The components bands of amide I, II, and III regions were assigned using 
Fourier self-deconvolution (FSD) and second derivative resolution with curve 
fitting as shown in Figure 9. 
For amide I band, the components are assigned as follows: 1606 - 1620 cm−1 
represent β-sheet, 1620 - 1647 cm−1 represent random coil, 1649 to 1670 cm−1 
correspond to α-helix, 1672 - 1687 cm−1 to turn structure and 1687 - 1700 cm−1 
correspond to β-antiparallel. For amide II region, the absorption bands are as-
signed in the following order: 1487-1506 cm−1 to β-sheet, 1506 - 1523 cm−1 to 
random coil, 1523 - 1558 cm−1 to α-helix, 1560 - 1585 cm−1 to turn structure and 
1585 - 1600 cm−1 to β-antiparallel. For amide III region, the bands are assigned  
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Figure 9. Fourier self-deconvolutions (FSD) spectra subtraction: top {free HSA - 
HSA-DA (0.7 mM)}, bottom the final result of the subtraction. 
 
as follows: 1220 - 1256 cm−1 to β-sheet, 1259 - 1287 cm−1 to random coil, 1288 - 
1302 cm−1 to turn structure, and 1302 - 1331 cm−1 to α-helix. Most investigations 
have revealed that amid I bands are most sensitive in contributing to the sec-
ondary structure change however many studies reported informational contri-
bution from amide II and III and can be used to study the secondary structure of 
protein. [50] [51] [52]. 
In this work, the percentage of each secondary element of HSA secondary 
structure were calculated using normalization to integrate areas of the compo-
nents bands in amide I, II, and III divided by the total area. The obtained values 
represent relative intensities for each of the secondary element with the specified 
region while the area under each secondary element corresponds to its percen-
tage. Figure 10 shows the percentages determination for the secondary structure 
of HSA in amide I region. Similar figures were obtained for each of amide II and 
amide III regions. The obtained data in Table 2 is extracted from Figure 10 and 
curve-fitted for amide I, II and III regions and secondary structure determina-
tions of the HSA free and its DA various complexes in dehydrated films. The ta-
ble clearly lists the percentages of each secondary structure of HSA before and 
after the interaction with DA at different concentration. As a general trend, as 
DA concentrations are increased, α-helix percentage increased in the three 
amide regions which is accompanied by overall decrease β-sheet percentages in 
the same regions. 
The increase in α-helix percentage and the decrease in β-sheets are believed to 
be due to the unfolding of the HSA in the presence of DA because of weak  
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Figure 10. Deconvolution curve for determination the percentages for second-
ary structure of HSA in amide I. 
 
Table 2. Secondary structure determination for amide I, amide II, and amide III regions for HSA free and HSA-DA complexes. 
Bands Range (cm−1) Intensity % Intensity % Intensity % Intensity % Intensity % Intensity % 
  Free HSA 0.3 mM 0.4 mM 0.5 mM 0.6 mM 0.7 mM 
Amide I 1700 - 1600 (cm−1) 
β-sheets 1614 - 1628 3 5 3 3 1 1 
Random 1628 - 1643 12 11 11 9 11 11 
α-helix 1645 - 1672 65 56 65 55 68 70 
Turns 1674 - 1687 13 14 13 16 12 11 
β-sheets (Anti) 1689 - 1700 7 14 8 17 8 7 
Amide II 1600 - 1480 (cm−1) 
β-sheets 1484 - 1500 7 6 5 6 6 6 
Random 1502 - 1531 25 19 17 13 18 19 
α-helix 1533- 1564 22 20 32 26 32 34 
Turns 1564 - 1585 19 20 18 18 18 18 
β-sheets 
anti 1585 - 1600 27 35 28 37 26 23 
Amide III 1320 - 1220 (cm−1) 
β-sheets 1222 - 1255 47 36 36 30 39 30 
Random 1257 - 1281 18 18 19 19 20 20 
Turns 1281 - 1302 15 20 23 28 20 29 
α-helix 1302 - 1317 20 26 22 23 21 21 
1700 1680 1660 1640 1620 1600
Ab
so
rp
tio
n 
(A
U)
Wavenumber (cm-1)
 Free HSA
 0,3 mM DA
 0,4 mM DA
 0,5 mM DA
 0,6 mM DA
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intermolecular forces between HSA and DA at C=O and C—N—H groups. This 
intermolecular interaction which is mainly due to collisions and weak interac-
tions due to electrostatic forces between the HSA and DA causing unfolding of 
HSA to increase thus increasing the α-helix percentage. [15] [16] [34] [35]. It 
seems that the electrostatic forces between HSA and DA increase bonding in 
α-helix which is accompanied by decrease in β-sheets due to destabilization ef-
fects due to fast dynamic equilibrium which is consistent with the small binding 
constant value obtained from fluorescence in addition to weak hydrophobic 
contacts. 
5. Discussion/Conclusions 
In conclusion, the complexation of HSA-DA has been investigated using UV 
absorption spectroscopy, fluorescence spectroscopy, and FT-IR under physio-
logical conditions. DA binds to HSA with binding constant of 4.4 × 102 and 
quenching constant of 1.32 × 109 L∙mol−1∙s −1 at 25˚C. 
The UV investigation repeatedly showed no complexation and a value for the 
binding constant was not determined due to the very weak interaction between 
DA and HSA when compared to added absorbance signals of individual absorb-
ing HSA and DA. Fluorescence investigations indicate that the original fluores-
cence of HSA was quenched by DA through dynamic quenching mechanism 
which is consistent with the obtained value of quenching constants. Simply, DA 
must diffuse to HSA during the lifetime of the excited state. Once diffused and 
upon contact, Trp214 returns to its ground state. The small binding constant is 
in agreement with the quenching constant value. 
There are several ways to distinguish between dynamic and static quenching. 
The first is to realize that upon complexation the newly formed complex usually 
has a different absorption spectrum from either of the complex components, 
therefore, changes on the absorption spectra are almost a diagnostic of a static 
quenching mechanism. The second hint usually is evident from the shape of the 
absorption spectra. Linear Stern-Volmer is almost always due to static quench-
ing while non-linear is almost definitive criteria for either dynamic quenching 
due to purely collisional frequency or due to a mix of both static and dynamic 
quenching. Although dynamic and static processes are concurrently present in 
many systems, it is very important to realize the distinctive feature of the ab-
sorption spectra of such systems which result in an upward curvature which is 
not the case in HSA-DA system. Similar behavior in shape of the absorption 
spectra might be obtained in cases where there is more than one fluorophore ac-
cessible to the quencher i.e., DA. In such cases, DA quenched Trp214 fluoro-
phores on the surface but was not able to penetrate the hydrophobic interior of 
HSA due to hydrophobic forces from within the bulky HSA or the presence of 
charged quenchers such as the chloride ion of the dopamine hydrochloride and 
as a result DA would have limited surface intermolecular interaction due to in-
accessibility of the interior Trp214 residue sites and only those residues on the 
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surface of the protein would be quenched. This is consistent with our findings in 
terms of fraction accessible for quenching of 5%. This behavior has been ob-
served in protein fluorophore quenching by polar or charged quenchers. As a 
result, Stern-Volmer plots deviate from linearity toward the x-axis. 
FT-IR spectra indicate increase in partial unfolding of the protein upon DA 
binding due to weak intermolecular hydrophobic electrostatic forces. The FT-IR 
results are consistent with fluorescence investigation. 
The results reported in this paper are helpful to improve the understanding of 
the HSA interaction with DA. The biological significance of this investigation 
lies in the well-recognized role of HSA as a drug transporter to target specified 
organs in such a way that the target organ could be cured therefore it is very 
important to understand the various types of molecular interactions of HSA with 
drugs are essential in the drug delivery and in promotion alternative foundations 
for new pathways of drug delivery. DA is delivered using  
L-3,4-dihydroxyphenylalanine (L-DOPA), which is the precursor of DA, in 
treatment of Parkinson’s disease due to lack of dopamine. We look forward to 
developing alternative ways to deliver DA more effectively instead of converting 
the precursor to dopamine. Now that we have such results indicating the 
quenched nature for fluorescence quenching, this could be the beginning to de-
velop alternatives ways for enhancing the HSA-DA interactions enhancement to 
be able to deliver DA directly. Possible ways to achieve this goal could be by ei-
ther derivatization of DA or by using nanoparticles functionalization. 
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